It is associated with drawbacks such as injection pain, injection site dystrophy, inconvenience, social distress and/or injection phobia
For CJC-1295 with DAC, research protocols commonly reference doses in the range of 1-2mg per week, sometimes split into two administrations
Weight loss tends to be faster in the first six months, gradually slowing and plateauing around 18 months
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (CagriSema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
A controlled study
Observed molecular and physiological responses are dependent on experimental design, concentration, and model system, and are used to investigate GHRH receptor signalling rather than defined biological or physiological outcomes